Skip to main content

LCD L33575: Varicose Veins of the Lower Extremity, Treatment of

LCD L33575, Varicose Veins of the Lower Extremity, Treatment of, is the Local Coverage Determination that Wellpoint Federal applies to claims from 10 states (CT, IL, MA, ME, MN, NH, NY, RI and others), effective 2026-04-01 and first in force 2015-10-01. The policy text runs 601 words, and its billing and coding article A52870 lists 45 ICD-10-CM codes that support medical necessity for 23 procedure codes. 1 other contractor version share this title, so the criteria depend on where the service is furnished. Counting every linked billing and coding article, this one lists 45 covered ICD-10-CM codes: 1 fewer code than L34082 (CGS Administrators, LLC, 46 codes, revised 2026-10-08).

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: Medicare Coverage Database LCD export: MCD release November 12, 2026 (effective November 8, 2026); Medicare Coverage Database billing and coding articles: MCD release November 12, 2026 (effective November 8, 2026). Next CMS release: weekly, every Thursday.

Contractor
Wellpoint Federal
States and territories
10
CT IL MA ME MN NH NY RI VT WI
Revision effective
2026-04-01
Original effective
2015-10-01
Policy text
601 words
Covered ICD-10 codes (articles)
45

Where this LCD applies

Each contract number is a jurisdiction on the remittance; the policy binds claims processed under these contracts and no others.

Contracts that apply LCD L33575
ContractContractorTypeStates
06101Wellpoint FederalMAC - Part AIL
06201Wellpoint FederalMAC - Part AMN
06301Wellpoint FederalMAC - Part AWI
06102Wellpoint FederalMAC - Part BIL
06202Wellpoint FederalMAC - Part BMN
06302Wellpoint FederalMAC - Part BWI
13101Wellpoint FederalA and B and HHH MACCT
13201Wellpoint FederalA and B and HHH MACNY
13102Wellpoint FederalA and B and HHH MACCT
13202Wellpoint FederalA and B and HHH MACNY
13282Wellpoint FederalA and B and HHH MACNY
13292Wellpoint FederalA and B and HHH MACNY
14411Wellpoint FederalA and B and HHH MACRI
14211Wellpoint FederalA and B and HHH MACMA
14311Wellpoint FederalA and B and HHH MACNH
14511Wellpoint FederalA and B and HHH MACVT
14111Wellpoint FederalA and B and HHH MACME
14112Wellpoint FederalA and B and HHH MACME
14212Wellpoint FederalA and B and HHH MACMA
14312Wellpoint FederalA and B and HHH MACNH
14512Wellpoint FederalA and B and HHH MACVT
14412Wellpoint FederalA and B and HHH MACRI

Billing and coding article A52870: diagnoses and procedure codes

Since 2019 the codes live in the companion article rather than the LCD. Billing and Coding A52870 (Billing and Coding: Treatment of Varicose Veins of the Lower Extremity) carries the diagnosis and procedure lists the contractor loads as the claims edit. CPT codes are shown as bare numbers because the descriptors are licensed by the AMA; HCPCS Level II descriptors are public and shown. Each article below opens its complete covered and non-covered ICD-10-CM lists, by group and with the contractor's group instructions, and the LCD code lookup answers whether one diagnosis is covered for one procedure code in a given state.

Coverage is only half of the claim edit: when two of the listed procedure codes are billed on the same date, test the pair against the NCCI edits before relying on both being paid.

A52870: Billing and Coding: Treatment of Varicose Veins of the Lower Extremity (Billing and Coding, effective 2026-04-01)

Covered ICD-10-CM codes
45
1 group
Non-covered ICD-10-CM codes
19
Procedure codes listed
23
Full article
cms.gov record
First 24 covered ICD-10-CM codes in A52870
ICD-10-CMDescription (FY2027)
I80.01Phlebitis and thrombophlebitis of superficial vessels of right lower extremity
I80.02Phlebitis and thrombophlebitis of superficial vessels of left lower extremity
I80.03Phlebitis and thrombophlebitis of superficial vessels of lower extremities, bilateral
I80.3Phlebitis and thrombophlebitis of lower extremities, unspecified
I83.011Varicose veins of right lower extremity with ulcer of thigh
I83.012Varicose veins of right lower extremity with ulcer of calf
I83.013Varicose veins of right lower extremity with ulcer of ankle
I83.014Varicose veins of right lower extremity with ulcer of heel and midfoot
I83.015Varicose veins of right lower extremity with ulcer other part of foot
I83.018Varicose veins of right lower extremity with ulcer other part of lower leg
I83.021Varicose veins of left lower extremity with ulcer of thigh
I83.022Varicose veins of left lower extremity with ulcer of calf
I83.023Varicose veins of left lower extremity with ulcer of ankle
I83.024Varicose veins of left lower extremity with ulcer of heel and midfoot
I83.025Varicose veins of left lower extremity with ulcer other part of foot
I83.028Varicose veins of left lower extremity with ulcer other part of lower leg
I83.11Varicose veins of right lower extremity with inflammation
I83.12Varicose veins of left lower extremity with inflammation
I83.211Varicose veins of right lower extremity with both ulcer of thigh and inflammation
I83.212Varicose veins of right lower extremity with both ulcer of calf and inflammation
I83.213Varicose veins of right lower extremity with both ulcer of ankle and inflammation
I83.214Varicose veins of right lower extremity with both ulcer of heel and midfoot and inflammation
I83.215Varicose veins of right lower extremity with both ulcer other part of foot and inflammation
I83.218Varicose veins of right lower extremity with both ulcer of other part of lower extremity and inflammation

Procedure codes: 36465, 36466, 36468, 36470, 36471, 36473, 36474, 36475, 36476, 36478, 36479, 36482, 36483, 37700, 37718, 37722, 37735, 37760, 37761, 37765, 37766, 37780, 37799.

Coverage indications, limitations and medical necessity

Indications:

Varicose veins are caused by venous insufficiency as a result of valve reflux (incompetence). The venous insufficiency results in dilated, tortuous, superficial vessels that protrude from the skin of the lower extremities. Spider veins (telangiectases) are dilated capillary veins that are most often treated for cosmetic purposes.

The accepted treatments for eliminating saphenous (great saphenous vein (GSV), anterior accessory GSV (AAGSV), small saphenous vein (SSV)) reflux (saphenofemoral or saphenopopliteal) are radiofrequency ablation (RFA), laser ablation (EVLA), polidocanol microfoam (PEM), cyanoacrylate embolization (CAE) ablation, and mechanochemical ablation (MOCA). Coverage is only for devices with FDA approval or clearance consistent with saphenous ablation and used according to its approved instructions for use (IFU).

RFA and EVLA are classified as thermal tumescent (TT) techniques; PEM, CAE and MOCA are non-thermal non-tumescent (NTNT) techniques. Each endovenous ablation approach has advantages and disadvantages; which one is best depends on the unique clinical/anatomical scenario. While saphenous vein ligation and stripping remains an important option in selected cases, it has been largely supplanted by endovenous ablation therapy as primary treatment of saphenous (axial/truncal) vein incompetence. The treatments to eliminate the saphenous vein reflux will be considered medically necessary if the patient remains symptomatic after a six-week trial of conservative therapy and has reflux in a saphenous vein.

The treatments for symptomatic varicose tributaries are either compressive sclerotherapy or microphlebectomy. The treatments of the tributary veins will be considered medically necessary if saphenous reflux is not present or already successfully eliminated, the veins are > than 4 mm in diameter and if the patient remains symptomatic after a six-week trial of conservative therapy.

The components of the conservative therapy include, but are not limited to:

• weight reduction,

• a daily exercise plan,

• periodic leg elevation, and

• the use of graduated compression stockings.

The conservative therapy must be documented in the medical record. Inability to tolerate compressive bandages or stockings and the reason for such intolerance must be documented in the medical record.

The patient is considered symptomatic if any of the following signs and symptoms of significantly diseased vessels of the lower extremities are documented in the medical record:

• stasis ulcer of the lower leg,

• significant pain and significant edema that interferes with activities of daily living,

• bleeding associated with the diseased vessels of the lower extremities,

• recurrent episodes of superficial phlebitis,

• stasis dermatitis, or

• refractory dependent edema.

Coverage of endovenous ablation therapy is limited to patients with:

• a maximum vein diameter of 12 mm for CAE, PEM and MOCA; and

• absence of thrombosis or vein tortuosity, which would impair catheter advancement (except for PEM).

Medicare includes payment for the ultrasound guidance in the payment for endovenous ablation procedures.

Limitations:

Coil embolization is non-covered for any varicose vein procedure.

The following interventional treatments are not considered medically reasonable or necessary and are denied as such:

• Surgery, endovenous ablation, or sclerotherapy are typically not performed for varicose veins that develop or worsen during pregnancy because most will spontaneously resolve or improve after delivery.

• Reinjection following recanalization or failure of vein closure without recurrent signs or symptoms.

• Sclerotherapy of the saphenous vein at its junction with the deep system.

• Noncompressive sclerotherapy.

• Compressive sclerotherapy for large, extensive or truncal varicosities.

• Sclerotherapy, ligation and/or stripping of varicose veins, or endovenous ablation therapy are generally not covered for patients with severe distal arterial occlusive disease; obliteration of deep venous system; an allergy to the sclerosant; or a hypercoaguable state.

• Any interventional treatment that uses equipment or sclerosants not approved for such purposes by the FDA.

Summary of evidence (opening)

Mechanochemical endovenous ablation

The impetus for alternatives to RFA and EVLA is the desire to eliminate the need for thermal energy which necessitates tumescent anesthesia and can cause pain and complications.

In a randomized control trial (RCT) involving MOCA, the “Venefit™ versus ClariVein for varicose veins trial”, 170 patients with symptomatic saphenous vein insufficiency were randomized to either MOCA or RFA (Bootun 2016, Lane 2016). MOCA was associated with significantly lower procedure related pain, and “occlusion rates, clinical severity scores, disease specific and generic quality of life scores were similar between groups at one and six months.”

Two non-randomized controlled studies have also been published. Van Eekeren prospectively compared MOCA with RFA in 68 consecutive patients (van Eekeren 2013). The treated great saphenous vein (GSV) was significantly wider at the saphenofemoral junction (SFJ) in the RFA group than in the MOCA group (P=.03). The primary endpoint, postoperative pain, was significantly less for MOCA initially and similar at 6 weeks. A major limitation to the study was that occlusion rates were not reported. The second prospective, non-randomized controlled study compared MOCA (n=57) with RFA (n=50) and EVLA (n=40) (Vun 2014). The MOCA group demonstrated significantly lower procedural pain scores and shorter treatment times, but occlusion rates beyond six weeks were not measured.

the full summary and analysis of evidence are in the CMS record.

Dates, lineage and related policies

Original determination effective
2015-10-01
Current revision effective
2026-04-01
Last reviewed by the contractor
2017-08-18
MCD version
44

Other related documents: A55704 (Response to Comments).

Using this policy on a claim

Match the documented indication to the covered indications above before the service is scheduled, carry a diagnosis from the article's covered list on the claim line (the diagnosis coverage checker tests one code pair against every article that applies in a state), and keep the elements the documentation section asks for in the record, because the contractor can request it later through medical review. A denial under this policy arrives as CARC 50 with remark N115; the LCD lookup guide walks through the appeal path and the Advance Beneficiary Notice rules, and the Wellpoint Federal hub lists every other active policy from the same contractor.

The same policy title at other contractors

Contractors often adopt each other's policies and then revise them separately, so the criteria and the diagnosis lists drift apart. The topic comparison lines up every version.

Prior authorization in Original Medicare

  • Hospital outpatient departments need prior authorization nationwide for dates of service on or after July 1, 2020; it is a condition of payment for the hospital claim and related claims. CMS service group: Vein ablation and related services. Codes on the CMS list: 36473, 36474, 36475, 36476, 36478, 36479, 36482 and 36483.
  • Ambulatory surgical centers in the CMS prior authorization demonstration: January 19, 2026 in California, Florida, Georgia, Maryland, New York, Pennsylvania and Tennessee; February 16, 2026 in Arizona, Ohio and Texas; requests are voluntary, and claims without one go to pre-payment review. CMS service group: Vein ablation and related services. Codes on the CMS list: 36473, 36475, 36478 and 36482; 36474, 36476, 36479 and 36483 were removed on January 1, 2026.

Medicare Advantage plans run their own prior authorization lists. See the services and codes on the Medicare prior authorization list.

For teams evaluating QuickIntell software

Where QuickIntell fits with this policy

If your team repeatedly reviews local coverage policies, explore QuickAuth for requirement checks, documentation and status tracking with staff oversight. Confirm the applicable policy, supported workflow and review responsibilities. Use QuickRCM to evaluate the separate claim and denial workflow.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions

What does LCD L33575 cover?

Varicose veins are caused by venous insufficiency as a result of valve reflux (incompetence). The venous insufficiency results in dilated, tortuous, superficial vessels that protrude from the skin of the lower extremities. Spider veins (telangiectases) are dilated capillary veins that are most often treated for cosmetic purposes. The full 601-word policy text is reproduced below from the Medicare Coverage Database export of November 12, 2026.

Which states does LCD L33575 apply to?

Wellpoint Federal applies it to Medicare claims in 10 states: CT, IL, MA, ME, MN, NH, NY, RI, VT, WI. It binds only that contractor; 1 other contractor version of this title governs other jurisdictions, and elsewhere the same service is judged under the local contractor's own policy or, where none exists, claim by claim.

Which diagnosis codes support medical necessity under LCD L33575?

The companion billing and coding article A52870 lists 45 ICD-10-CM codes in 1 group that support medical necessity and 19 that do not; the first 24 appear on this page, where the complete list opens by group with the contractor's group instructions.

How do I appeal a denial under LCD L33575?

A denial under LCD L33575 carries claim adjustment reason code 50 with remark code N115. Compare the documented indication with the policy's covered indications and article A52870's 45 covered diagnosis codes, then file a redetermination with Wellpoint Federal within 120 days, record attached. If the service falls outside the policy, bill the patient only with a valid Advance Beneficiary Notice signed before the service.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

The policy text and code lists are reproduced from the CMS Medicare Coverage Database export as an operational reference. Verify against the current LCD and article on cms.gov before billing; coverage depends on the full record and the contractor. Not legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.